Search: WFRF:(Vanbrabant J.) >
Combination of plas...
Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
-
- Verberk, Inge M.W. (author)
- Vrije Universiteit Amsterdam
-
- Thijssen, Elisabeth (author)
- Vrije Universiteit Amsterdam
-
- Koelewijn, Jannet (author)
- Vrije Universiteit Amsterdam
-
show more...
-
- Mauroo, Kimberley (author)
- ADx NeuroSciences
-
- Vanbrabant, Jeroen (author)
- ADx NeuroSciences
-
- De Wilde, Arno (author)
- Vrije Universiteit Amsterdam
-
- Zwan, Marissa D. (author)
- Vrije Universiteit Amsterdam
-
- Verfaillie, Sander C.J. (author)
- Vrije Universiteit Amsterdam
-
- Ossenkoppele, Rik (author)
- Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Vrije Universiteit Amsterdam
-
- Barkhof, Frederik (author)
- University College London
-
- Van Berckel, Bart N.M. (author)
- Vrije Universiteit Amsterdam
-
- Scheltens, Philip (author)
- Vrije Universiteit Amsterdam
-
- Van Der Flier, Wiesje M. (author)
- Vrije Universiteit Amsterdam
-
- Stoops, Erik (author)
- ADx NeuroSciences
-
- Vanderstichele, Hugo M. (author)
- ADx NeuroSciences
-
- Teunissen, Charlotte E. (author)
- Vrije Universiteit Amsterdam
-
show less...
-
(creator_code:org_t)
- 2020-09-28
- 2020
- English.
-
In: Alzheimer's Research and Therapy. - : Springer Science and Business Media LLC. - 1758-9193. ; 12:1
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://alzres.biome...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: Blood-based biomarkers for Alzheimer's disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the potential of plasma markers Abeta(1-42/1-40), glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) to identify cerebral amyloidosis and/or disease severity. Methods: We included individuals with a positive (n = 176: 63 ± 7 years, 87 (49%) females) or negative (n = 76: 61 ± 9 years, 27 (36%) females) amyloid PET status, with syndrome diagnosis subjective cognitive decline (18 PET+, 25 PET-), mild cognitive impairment (26 PET+, 24 PET-), or AD-dementia (132 PET+). Plasma Abeta(1-42/1-40), GFAP, and NfL were measured by Simoa. We applied two-way ANOVA adjusted for age and sex to investigate the associations of the plasma markers with amyloid PET status and syndrome diagnosis; logistic regression analysis with Wald's backward selection to identify an optimal panel that identifies amyloid PET positivity; age, sex, and education-adjusted linear regression analysis to investigate associations between the plasma markers and neuropsychological test performance; and Spearman's correlation analysis to investigate associations between the plasma markers and medial temporal lobe atrophy (MTA). Results: Abeta(1-42/1-40) and GFAP independently associated with amyloid PET status (p = 0.009 and p < 0.001 respectively), and GFAP and NfL independently associated with syndrome diagnosis (p = 0.001 and p = 0.048 respectively). The optimal panel identifying a positive amyloid status included Abeta(1-42/1-40) and GFAP, alongside age and APOE (AUC = 88% (95% CI 83-93%), 82% sensitivity, 86% specificity), while excluding NfL and sex. GFAP and NfL robustly associated with cognitive performance on global cognition and all major cognitive domains (GFAP: range standardized β (sβ) = - 0.40 to - 0.26; NfL: range sβ = - 0.35 to - 0.18; all: p < 0.002), whereas Abeta(1-42/1-40) associated with global cognition, memory, attention, and executive functioning (range sβ = 0.22 - 0.11; all: p < 0.05) but not language. GFAP and NfL showed moderate positive correlations with MTA (both: Spearman's rho> 0.33, p < 0.001). Abeta(1-42/1-40) showed a moderate negative correlation with MTA (Spearman's rho = - 0.24, p = 0.001). Discussion and conclusions: Combination of plasma Abeta(1-42/1-40) and GFAP provides a valuable tool for the identification of amyloid PET status. Furthermore, plasma GFAP and NfL associate with various disease severity measures suggesting potential for disease monitoring.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Klinisk laboratoriemedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Clinical Laboratory Medicine (hsv//eng)
Keyword
- Alzheimer's continuum
- Amyloid pathology
- Blood-based biomarkers
- Plasma amyloid beta
- Plasma GFAP
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Verberk, Inge M. ...
-
Thijssen, Elisab ...
-
Koelewijn, Janne ...
-
Mauroo, Kimberle ...
-
Vanbrabant, Jero ...
-
De Wilde, Arno
-
show more...
-
Zwan, Marissa D.
-
Verfaillie, Sand ...
-
Ossenkoppele, Ri ...
-
Barkhof, Frederi ...
-
Van Berckel, Bar ...
-
Scheltens, Phili ...
-
Van Der Flier, W ...
-
Stoops, Erik
-
Vanderstichele, ...
-
Teunissen, Charl ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Clinical Laborat ...
- Articles in the publication
-
Alzheimer's Rese ...
- By the university
-
Lund University